fundvisualizer.com

Delaware Healthcare IDLHIX

Performance (before sales charge)

As of 06/30/2024

All information is historical and not indicative of future results. Current performance may be lower or higher than the quoted past performance, which cannot guarantee results. Share price, principal value, and return will vary, and you may have a gain or a loss when you sell your shares. Performance assumes reinvestment of distributions and does not account for taxes. After-sales-charge returns reflect the maximum sales charge applicable to the fund. Performance may not reflect any expense limitation or subsidies currently in effect. Short-term trading fees may apply. To obtain the most recent month-end performance, visit Morningstar.com.

Asset allocation

As of 05/31/2024
Stock
83.98%
Non-U.S. Stock
14.34%
Bond
0.00%
Non-U.S. Bond
0.00%
Preferred
0.00%
Convertible
0.00%
Cash
1.67%
Other
0.00%

Due to rounding, percentages may not equal 100%.

Sectors

As of 05/31/2024

Basic materials

0.15%

Consumer cyclical

0.00%

Financial services

0.46%

Real estate

0.00%

Consumer defensive

0.47%

Health care

96.60%

Utilities

0.00%

Communication services

0.63%

Energy

0.00%

Industrials

0.00%

Technology

0.00%

Top 10 holdings

As of 05/31/2024

Eli Lilly and Co
12.84%
Amgen Inc
6.98%
Regeneron Pharmaceuticals Inc
6.52%
UnitedHealth Group Inc
4.91%
Merck & Co Inc
4.83%
Elevance Health Inc
4.43%
Pfizer Inc
4.28%
Boston Scientific Corp
3.75%
AbbVie Inc
2.73%
Viking Therapeutics Inc
2.68%
Fund assets

$784.16 Million

Share class

Inst

Morningstar category

Health

Expense ratio

0.96%

Investment objective

Specialty - Health

Documents